academic article

• Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control..  Journal of medical economics.  18:113-125. 2015
• Quality measure attainment in patients with type 2 diabetes mellitus..  The American journal of managed care.  20:s5-15. 2014
• Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings..  Journal of medical economics.  15:352-360. 2012
• Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease..  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.  25:493-500. 2010
• Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients..  Journal of medical economics.  13:673-680. 2010
• Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective..  Journal of managed care pharmacy : JMCP.  15:312-322. 2009